BT PHARMA has an exclusive license from the Institut Pasteur related to three patent families that protect its core recombinant adenylate cyclase vector (CyaA) technology. The exclusive license covers all vaccine and immuno-therapeutic applications for human and veterinary use*.

BT PHARMA continuously improves its technology platform and has a policy to regularly protect those improvements and inventions through new patent applications.

BT PHARMA’s PepTel® technology is protected by two patent families.

* except Malaria, TB, HIV and melanoma